Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 12/12 08:29:08 pm
172.64 USD   -0.07%
03:04p ALLERGAN : Receives FDA Clearance For the CoolSculpting® Treatment T..
12/08 TEVA CONSIDERIN : Bloomberg
12/08 TEVA CONSIDERIN : Bloomberg
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Allergan : Receives Refusal to File Letter from FDA for Vraylar® cariprazine Supplemental New Drug Application sNDA for the Treatment of Negative...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:46pm CET

Allergan Receives Refusal to File Letter from FDA for Vraylar® cariprazine Supplemental New Drug Application sNDA for the Treatment of Negative Symptoms in Schizophrenia

By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Allergan plc (NYSE: AGN) announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for Vraylar (cariprazine) for treatment of negative symptoms associated with schizophrenia in adult patients. VRAYLAR is an oral, once daily atypical antipsychotic approved in the United States for the treatment of schizophrenia and the acute treatment of adult patients with manic or mixed episodes associated with bipolar I disorder (see also Allergan plc).

Upon its preliminary review, FDA determined that the sNDA for treatment of negative symptoms was not sufficiently complete to permit a substantive review.

"We are disappointed with the FDA decision on our submission. We will request a meeting with FDA to discuss and determine our next steps. Vraylar is an important treatment option for patients suffering from bipolar I disorder and schizophrenia. We remain committed to our mental health program and to cariprazine and its potential as a treatment option for patients suffering from negative symptoms associated with schizophrenia," said David Nicholson Ph.D., Chief Research & Development Officer, Allergan.

Schizophrenia is a chronic and disabling disorder that includes positive symptoms (i.e. hallucinations, delusions and thought disorders) and negative symptoms (i.e. loss of motivation and social withdrawal). These symptoms are strongly associated with long term morbidity, poor psychosocial functioning and considerable social and economic costs.

Cariprazine is approved in Europe for the treatment of schizophrenia. The approval includes data from the 460-patient negative symptoms study which was conducted by Gedeon Richter and published in the Lancet on February 6, 2017.

The Company will seek immediate guidance, and is in the process of planning a meeting with the FDA, to respond to the issues, and to seek clarification of what additional information will be required.

Keywords for this news article include: Psychiatry, FDA Actions, Allergan plc, Schizophrenia, Mental Health Diseases and Conditions, Government Agencies Offices and Entities.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
03:04p ALLERGAN : Receives FDA Clearance For the CoolSculpting® Treatment To Improve Ap..
12/08 TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
12/08 TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
12/07 ALLERGAN : Migraine Leadership Recognized with Enrico Greppi Award for Excellenc..
12/07 EDITAS MEDICINE : BioCentury - Editas raises $50M follow-on
12/01 Tech firms tell patent court to ignore Allergan deal with tribe
11/30 ALLERGAN : to Present at the 2017 Citi Global Healthcare Conference
11/29DJALLERGAN : Health Care Up on Rotation Out of Tech -- Health Care Roundup
11/29 ALLERGAN : Migraine Leadership Recognized with Enrico Greppi Award for Excellenc..
11/24 ALLERGAN : to Present at the 2017 Citi Global Healthcare Conference
More news
News from SeekingAlpha
07:00a Amgen to acquire Repros for $0.67 per share
12/11 Is The Valeant, Ackman Insider Trading Case Finally Here?
12/11 ALLERGAN : Is Revance The Botox Killer?
12/11 YOUR DAILY PHARMA SCOOP : Celgene Upside, Erytech Tumbles, Novartis Neulasta Bio..
12/11 Allergan - I Am Allergic To Aggressive Practices
Financials ($)
Sales 2017 15 894 M
EBIT 2017 7 658 M
Net income 2017 -5 870 M
Debt 2017 24 765 M
Yield 2017 1,66%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 5,17x
EV / Sales 2018 5,13x
Capitalization 57 457 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 225 $
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-21.49%57 457
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.15%218 773
PFIZER9.30%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659